Back to results
US 2022/0064132 A1Published application
Leukotriene synthesis inhibitors
AssigneeNaegis Pharmaceuticals Inc.
InventorsDavid L. Burgoyne, Erin Debruin, Julia Fonarev, James Gee Ken Yee, John Michael Langlands
Life of this patent
Estimating the term…
Abstract
Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
Claims21
A compound of formula (1)
- or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:
- Ar is unsubstituted or is substituted with one or two substituents selected from halide, C1-6alkyl;
- —S—C1-6alkyl;
- —O—C1-6alkyl;
- and —SO2—C1-6alkyl;
- L is selected from a direct bond and —CH2— (methylene);
- R1 is selected from hydrogen, halide, C1-C6alkyl, C1-C6haloalkyl and C1-C6alkoxy;
- A is selected from a direct bond, —CH2— and —CH2CH2—;
- E is selected from —C(O)—R2, C(OR3)R4R5 and CH(R6)NR7R8;
- R2 is selected from methyl, ethyl and phenyl;
- R3 is H;
- R4 is selected from hydrogen, C1-C7alkyl and phenyl;
- R5 is selected from C1-C7alkyl, C1-C7haloalkyl, phenyl and halophenyl;
- R6 is selected from hydrogen, methyl, halogenated methyl and ethyl;
- and
- R7 is hydrogen and R8 is hydrogen, methyl or ethyl;
- or R7 and R8 together form a 5- or 6-membered heterocycle which is optionally substituted with a substituent selected from C1-C6alkyl and carboxylic acid.
14 more elements
A compound of formula (1)
- or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:
- Ar is a 9- or 10-membered bicyclic aromatic ring system, where Ar is optionally substituted with one, two or three substituents;
- L is selected from a direct bond and methylene;
- R1 is selected from hydrogen, halide, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C3-C6cycloalkoxy and C1-C6alkoxy substituted with C3-C6cycloalkyl;
- A is selected from a direct bond, —CH2— and —CH2CH2—;
- E is selected from —C(O)—R2, C(OR3)R4R5 and CH(R6)NR7R8;
- R2 is selected from methyl, ethyl and phenyl;
- R3 is selected from H, alkyl and substituted alkyl;
- R4 is selected from hydrogen, alkyl and phenyl;
- R5 is selected from C1-C7alkyl, C1-C7haloalkyl, phenyl and substituted phenyl;
- R6 is selected from hydrogen, methyl, halogenated methyl and ethyl;
- R7 is hydrogen;
- and R8 is hydrogen, methyl or ethyl;
- with the proviso that together, R7 and R8 may form a 5 or 6-membered, optionally substituted, heterocycle.
11 more elements
-102. (canceled)
Dependencies are inferred from the claim text.